SAN DIEGO, May 15, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from the Phase 3 CAHtalyst™ Adult and Pediatric studies of CRENESSITY™ (crinecerfont).

Changes in GC doses and A4 levels (measured before the morning GC dose) were analyzed using waterfall charts based on ... alters the production of adrenal steroid hormones, such as cortisol ...

The absence of endogenous cortisol results in increased secretion of corticotropin-releasing factor and adrenocorticotropic hormone (ACTH), which in turn drive excess production of adrenal androgens.

Hormones cause oil glands to enlarge and produce more oil during puberty and throughout the teen years. Hormonal fluctuations ...

Eton Pharma's Khindivi has won FDA approval as a pediatric adrenal insufficiency treatment. It is projected to surge in sales ...

The U.S. Food and Drug Administration said on Wednesday it has approved the expanded use of Merck's cancer drug to treat two ...

Mineralys Therapeutics, Inc.'s lorundrostat shows promise for treating aldosterone-driven hypertension with FDA approval by ...

Acerand Therapeutics, a clinical-stage biotech company focusing on the discovery and development of innovative small-molecule ...

The following is a summary of “Cytological Assessment of Adrenal Tumours: Insights From 22-Years Single Centre Experience,” published in the April 2025 issue of Clinical Endocrinology by Carasel et al ...